No abstract

Objective: The objective of the study was to compare the prevalence of endovenous heat-induced thrombosis (EHIT) in thromboprophylaxis with rivaroxaban versus none thromboprophylaxis in ablation with radiofrequency (RF) ablation. Methods: A retrospective, observational design of cases and controls of patients with chronic venous insufficiency was reviewed after the procedure of truncal ablation with RF. Group 1 did not receive thromboprophylaxis after the surgery. Group 2 received 10 mg of rivaroxaban every 24 h for a 2-week period. The presence of EHIT was evaluated during the 3 rd and 7 th days of post-surgery. Results: Between January 2013 and December 2017, a total of 113 patients were evaluated with 132 procedures. As a result, we found a significant difference in the total of procedures in favor of thromboprophylaxis with rivaroxaban decreasing the EHIT by p ≤ 0.0031 and odds ratio 8.5 with a confidence interval of 95% (2.10-39.9). Conclusion: The use of rivaroxaban was effective in the thromboprophylaxis of EHIT in the venous ablation with RF.

Objective:The aim of the study was to determine the risk factors associated with skin ulcers that were not of vascular, paraneoplastic, rheumatologic, or pressure origin. Methods: This was an observational, case-and control-designed, and retrospective trial. The group of cases was patients who presented skin ulcers that were not of vascular, paraneoplastic, or pressure origin. The control group was formed by ill subjects with no skin ulcers paired in age, sex, and chronic diseases. The cases were defined with the presence of an ulcer, at the 1 st time consultation; treatment with medication, symptoms, progression time, and substance abuse were entered in a database. The statistical analysis of the results was performed using the EpiInfo software, version 7.2.2.6. Results: Between July 2005 and December 2020, 69 patients suffering from skin ulcers without apparent etiology were enrolled. Following the statistical analysis of all variables, a significant difference in favor of the cases with antihypertensive treatment with angiotensin II receptor blockers (ARBs) was obtained, with p ≤ 0.02 and odds ratio 2.24 with confidence interval 95 % (1. 1-4.5). Conclusion: ARB medications are a risk factor for the presence of skin ulcers.